Clinical Trial Update: Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy [Phase 3]

View source ↗

Summary

Phase 3 trial of sunitinib plus prednisone in metastatic castration-resistant prostate cancer after docetaxel failure; the study was terminated and results were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• PREDNISONE (Prednisone)
• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Prostatic Neoplasms | Phase 3 | Status: TERMINATED | Results posted: 2013-03-08